anti-HER2 CAR T-cell therapy (Takara Bio/University Health Network)

N/A

Report date: 2025/06/11 10:39:41

Base Information

Drug Nameanti-HER2 CAR T-cell therapy (Takara Bio/University Health Network)
Drug Alias NameHER2-JAK/STAT-CAR-T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsSTAT transcription factors stimulantsT lymphocytes stimulants +[5] 
TargetsJanus kinaseSTAT transcription factorsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Health Network (Uhn)
China Registration ClassN/A

Develop Information

Active CompaniesTakara Bio IncUniversity Health Network (Uhn)
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A